Cornea | Ophthalmology Innovation Source

Refractec – The Tale of an Evolution in Need of a Revolution

Refractec was really a revolution at the time in terms of reshaping the cornea, but was in need of an evolution of how we think of the cornea. This technology if introduced today would have had an even more robust life. Presenter: Tom Frinzi Thomas Frinzi is Senior Vice President of Abbott’s vision business, which…

Dry Eye Challenges & Opportunities

Up to 60% of ophthalmologist patients have some form of ocular surface disease impacting over 60 million Americans. A Gallop poll of dry eye sufferers shows: 72% of patients use an artificial tear. 82% wish that there was something more effective to treat dry eye. 97% say that their dry eye condition is frustrating. The…

Cross Linking – Panel Discussion

Moderators: Stephen Slade, MD Stephen Glenn Slade graduated from the University of Texas (Summa Cum Laude, Phi Beta Kappa) with a final, elective year spent at Guy’s Hospital in London. He completed a residency at LSU in New Orleans and fellowships at Baylor College of Medicine and Project ORBIS in New York. View Full Profile…

Sustained Ophthalmic Therapies Pave the Future for Ocular Therapeutix

Amarpreet Sawhney, President & CEO for Ocular Therapeutix, shares the company’s vision of becoming the leading developer of sustained ophthalmic therapies. Striving to improve patient outcomes, Amarpreet details the company’s proprietary technology that works across the front, back and surface of the eye. Presenter: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006,…

NPP Meets the Mark for Kala Pharmaceuticals

[creativ_media type=”vimeo” url=”https://vimeo.com/82003104″] Guillaume Pfefer, President & CEO, shares Kala Pharmaceutical’s breakthrough technology Nucleolus Penetrating Particle with the audience of the 5th Annual Ophthalmology Innovation Summit. Detailing how this technology benefits a variety of conditions, Guillaume explains how the NPP can be leveraged to treat, post cataract surgery inflammation, dry eye, plethoritis and a demonstration…

Refractive Cataract Surgery – Challenges & Opportunities

Jack Holladay, Clinical Professor of Ophthalmology for Baylor College of Medicine and Jim Mazzo, Retired President for Abbott Medical Optics and Executive Chair for Acufocus, lead a panel discussion on Refractive Cataract Surgery at the 2nd Annual Ophthalmology Innovation Summit on April 18, 2013. Lending expert insights into the current challenges and arising opportunities in…